Bladder cancer drug Anktiva approved for more patients
Published
The FDA expanded Anktiva, used with BCG, to adults whose high-risk bladder cancer stopped responding to BCG and has high-grade papillary tumors only. In its earlier trial, 62% of patients had a complete response.
Source: U.S. Food and Drug Administration
This is a plain-language summary. Read the original source for full details.